Skip to content
← All treatment topics

TREATMENT READING

Childhood Extracranial Germ Cell Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

81 sections
  1. Follow-up After Treatment
  2. Treatment Option Overview for Childhood Extracranial GCTs
  3. Treatment Options for Childhood Extracranial GCTs by Histological Type
  4. GCTs with non-GCT elements (teratoma with malignant transformation)
  5. Surgery
  6. Surgery and Observation
  7. Chemotherapy
  8. Radiation Therapy
  9. Special Considerations for the Treatment of Children With Cancer
  10. Treatment of Mature and Immature Teratomas in Children
  11. Treatment of Mature Teratomas
  12. Standard treatment options for mature teratomas (sacrococcygeal sites)
  13. Standard treatment options for mature teratomas (nonsacrococcygeal sites)
  14. Treatment of Immature Teratomas
  15. Treatment options for immature teratomas
  16. Surgery and observation (stage I)
  17. Surgery and observation or chemotherapy (stages I–IV)
  18. Treatment options under clinical evaluation for immature teratomas
  19. Follow-up After Treatment of Mature and Immature Teratomas
  20. Treatment of Malignant Gonadal GCTs in Children
  21. Childhood Malignant Testicular GCTs
  22. Malignant testicular GCTs in prepubertal males
  23. Standard treatment options for malignant GCTs in prepubertal males
  24. Surgery and observation (stage I)
  25. Surgery and chemotherapy (stages II–IV)
  26. Malignant testicular GCTs in postpubertal males
  27. Standard treatment options for malignant testicular GCTs in postpubertal males
  28. Treatment options under clinical evaluation for malignant testicular GCTs
  29. Childhood Malignant Ovarian GCTs
  30. Dysgerminomas of the ovary
  31. Standard treatment options for dysgerminomas of the ovary
  32. Surgery and observation (stage I)
  33. Surgery and chemotherapy (stages II–IV)
  34. Malignant nongerminomatous ovarian GCTs
  35. Standard treatment options for malignant nongerminomatous ovarian GCTs
  36. Surgery and observation for prepubertal females (stage I following strict surgical staging guidelines)
  37. Surgery and chemotherapy for prepubertal and postpubertal females (purported stage I and stages II–IV)
  38. Initially unresectable ovarian GCT
  39. Treatment options under clinical evaluation for malignant ovarian GCTs
  40. Treatment of Malignant Extragonadal Extracranial GCTs in Children
  41. Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children
  42. Surgery and chemotherapy (stages I–IV)
  43. Biopsy followed by chemotherapy with or without surgery (stages III and IV)
  44. Site-specific considerations for malignant extragonadal extracranial GCTs
  45. Sacrococcygeal site
  46. Mediastinal site
  47. Retroperitoneal site
  48. Head and neck site
  49. Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Postpubertal Children
  50. Treatment Options Under Clinical Evaluation for Malignant Extragonadal Extracranial GCTs
  51. Treatment of Recurrent Malignant GCTs in Children
  52. Standard Treatment Options for Recurrent Malignant GCTs in Children
  53. Surgery with neoadjuvant or adjuvant chemotherapy
  54. Nonstandard Treatment Options for Recurrent Malignant GCTs in Children
  55. High-dose (HD) chemotherapy and hematopoietic stem cell rescue
  56. Radiation therapy followed by surgery (for brain metastases)
  57. Treatment Options Under Clinical Evaluation for Recurrent Malignant GCTs in Children and Adolescents
  58. Certain factors affect prognosis (chance of recovery) and treatment options.
  59. Childhood extracranial germ cell tumors usually do not come back after treatment.
  60. Treatment Option Overview
  61. Key Points
  62. There are different types of treatment for children with extracranial germ cell tumors.
  63. Children with extracranial germ cell tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.
  64. The following types of treatment are used:
  65. Surgery
  66. Observation
  67. Chemotherapy
  68. New types of treatment are being tested in clinical trials.
  69. High-dose chemotherapy with stem cell transplant
  70. Radiation therapy
  71. Treatment for childhood extracranial germ cell tumors may cause side effects.
  72. Patients may want to think about taking part in a clinical trial.
  73. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  74. Follow-up tests may be needed.
  75. Treatment of Childhood Mature and Immature Teratomas
  76. Treatment of Malignant Testicular Germ Cell Tumors
  77. Treatment of Malignant Ovarian Germ Cell Tumors
  78. Dysgerminomas
  79. Nongerminomas
  80. Treatment of Malignant Extragonadal Extracranial Germ Cell Tumors
  81. Treatment of Recurrent Childhood Malignant Extracranial Germ Cell Tumors

Health professional · General Information About Childhood Extracranial Germ Cell Tumors (GCTs)

Follow-up After Treatment

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The following tests and procedures may be performed at the physician's discretion for monitoring children with extracranial GCTs:

AFP and beta-hCG. Monitor AFP and beta-hCG levels monthly for 6 months (period of highest risk) and then every 3 months, for a total of 2 years (3 years for sacrococcygeal teratoma). A COG trial of patients with low-risk and intermediate-risk GCTs reported the following results:[73][Level of evidence C2]

Sources: 73 · Level of evidence C2

AFP and beta-hCG. Monitor AFP and beta-hCG levels monthly for 6 months (period of highest risk) and then every 3 months, for a total of 2 years (3 years for sacrococcygeal teratoma). A COG trial of patients with low-risk and intermediate-risk GCTs reported the following results:[73][Level of evidence C2]

Forty-eight patients with elevated tumor markers at diagnosis relapsed during the surveillance phase.

At the time of relapse (after central review), 47 of 48 (98%) relapses were detected by tumor marker elevation.

Imaging tests.

Imaging tests.

MRI/CT may be performed at the completion of therapy.

Guided imaging of the primary site may be performed every 3 months for the first year and every six months for the second year. Seminomas and dysgerminomas may recur later, so the imaging schedule may need to be extended.

Chest x-ray annually.

When tumor markers are normal at diagnosis, ultrasonography or CT/MRI may be performed every 3 months for 2 years and then annually for 5 years for germinomas.

Dramatic improvements in survival have been achieved for children and adolescents with cancer.[74] Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3,74,75] During the period from 2002 to 2010, cancer mortality continued to decrease by 2.4% per year for children and adolescents with gonadal tumors, as compared with the period from 1975 to 1998 (plateauing from 1998 to 2001).[74] Childhood and adolescent cancer survivors require close monitoring because late effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects of childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 74 · 3 · 74 · 75 · 74 · Late Effects of Treatment for Childhood Cancer

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment Option Overview for Childhood Extracranial GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Childhood extracranial germ cell tumors (GCTs) are very heterogenous.

On the basis of clinical factors and tumor histology, appropriate treatment for extracranial GCTs may involve one of the following:

Surgical resection followed by careful monitoring for disease recurrence.

Initial surgical resection followed by platinum-based chemotherapy.

Diagnostic tumor biopsy and preoperative platinum-based chemotherapy followed by definitive tumor resection.[1]

Sources: 1

To maximize long-term survival while minimizing treatment-related long-term sequelae (e.g., secondary leukemias, infertility, hearing loss, and renal dysfunction), children with extracranial malignant GCTs need to be cared for at pediatric cancer centers with experience treating these rare tumors.

Health professional · Treatment Option Overview for Childhood Extracranial GCTs

Treatment Options for Childhood Extracranial GCTs by Histological Type

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Table 7 provides an overview of treatment options for children with extracranial GCTs. Specific details of treatment by primary site and clinical condition are described in subsequent sections.

Sources: Table 7

Table 7. Treatment Options for Childhood Extracranial Germ Cell Tumors (GCTs)
HistologyTreatment Options
BEP = bleomycin (weekly), etoposide, and cisplatin; JEb = carboplatin, etoposide, and bleomycin; PEb = cisplatin, etoposide, and bleomycin (bleomycin only on day 1 of each cycle).
aChemotherapy has not been shown to be effective in the treatment of children with stages II–IV immature teratoma. However, the role of chemotherapy in these patients has not been systematically studied. In postpubertal patients, chemotherapy remains the standard treatment, although studies are limited.[2]
bIn prepubertal females with reported stage I disease, but in whom strict surgical staging guidelines were not followed, chemotherapy (PEb) can be considered standard treatment.[3]
cIn postpubertal females with stage I disease, the strategy of observation after surgery has not been established. This treatment strategy is under investigation in a clinical trial (AGCT1531 [NCT03067181]).
Mature teratoma
Sacrococcygeal siteSurgery and observation
Nonsacrococcygeal siteSurgery and observation
Immature teratomaSurgery and observation (stage I)
Surgery and observation or chemotherapy (stages I–IV) a
Malignant gonadal GCTs in children:
Childhood malignant testicular GCTs:
Malignant testicular GCTs in prepubertal malesSurgery and observation (stage I)
Surgery and chemotherapy (PEb) (stages II–IV)
Malignant testicular GCTs in postpubertal malesFor information, see Testicular Cancer Treatment.
Childhood malignant ovarian GCTs:
Dysgerminomas of the ovarySurgery and observation (stage I)
Surgery and chemotherapy (PEb) (stages II–IV)
Malignant nongerminomatous ovarian GCTs (yolk sac and mixed GCTs) in prepubertal femalesSurgery and observation for prepubertal females (stage I following strict surgical staging guidelines) b. For information about the treatment of ovarian mature teratoma, see the Childhood Malignant Ovarian GCTs section.
Surgery and chemotherapy (PEb) for prepubertal and postpubertal females (purported stage I and stages II–IV)
Malignant nongerminomatous ovarian GCTs (yolk sac and mixed GCTs) in postpubertal femalesSurgery and chemotherapy (BEP) for prepubertal and postpubertal females (purported stage I and stages II–IV) c
Malignant nongerminomatous ovarian GCTs (yolk sac and mixed GCTs) that are initially unresectableBiopsy followed by chemotherapy and surgery (initially unresectable ovarian GCT)
Malignant extragonadal extracranial GCTs in children:
Malignant extragonadal extracranial GCTs in prepubertal childrenSurgery and chemotherapy (PEb or JEb) (stages I –IV)
Biopsy followed by chemotherapy with or without surgery (stages III and IV)
Malignant extragonadal extracranial GCTs in postpubertal childrenSurgery
Chemotherapy (BEP)
Chemotherapy followed by surgery to remove residual tumor
Enrollment in a clinical trial
Recurrent malignant GCTs in childrenSurgery alone
Surgery with neoadjuvant or adjuvant chemotherapy

Sources: 2 · 3 · AGCT1531 [NCT03067181] · Surgery and observation · Surgery and observation · Surgery and observation (stage I) · Surgery and observation or chemotherapy (stages I–IV) · Surgery and observation (stage I) · Surgery and chemotherapy (PEb) (stages II–IV) · Testicular Cancer Treatment · Surgery and observation (stage I) · Surgery and chemotherapy (PEb) (stages II–IV) · Surgery and observation for prepubertal females (stage I following strict surgical staging guidelines) · Childhood Malignant Ovarian GCTs · Surgery and chemotherapy (PEb) for prepubertal and postpubertal females (purported stage I and stages II–IV) · Surgery and chemotherapy (BEP) for prepubertal and postpubertal females (purported stage I and stages II–IV) · Biopsy followed by chemotherapy and surgery (initially unresectable ovarian GCT) · Surgery and chemotherapy (PEb or JEb) (stages I –IV) · Biopsy followed by chemotherapy with or without surgery (stages III and IV) · Surgery · Chemotherapy (BEP) · Chemotherapy followed by surgery to remove residual tumor · Enrollment in a clinical trial · Surgery alone · Surgery with neoadjuvant or adjuvant chemotherapy

Health professional · Treatment Option Overview for Childhood Extracranial GCTs / Treatment Options for Childhood Extracranial GCTs by Histological Type

GCTs with non-GCT elements (teratoma with malignant transformation)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The treatment of GCTs with other non-GCT somatic elements is complex, and few data exist to direct treatment. In adolescents, central primitive neuroectodermal tumors and sarcomas have been found in teratomas.[4,5] The Italian Pediatric Germ Cell Tumor group identified 14 patients with malignant GCTs with a somatic malignancy, such as neuroblastoma or rhabdomyosarcoma, embedded in teratomas (<2% of extracranial GCTs).[6]

Sources: 4 · 5 · 6

The optimal treatment strategy for GCTs with non-GCT elements has not been determined. Separate treatments for both malignant GCTs and non-GCT elements may be required.

Health professional · Treatment Option Overview for Childhood Extracranial GCTs

Surgery

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Surgery is an essential component of treatment. Specific treatments will be discussed for each tumor type.

Health professional · Treatment Option Overview for Childhood Extracranial GCTs

Surgery and Observation

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

For patients with completely resected immature teratomas of all grades and at any location, and for patients with localized, completely resected (stage I) seminomatous and nonseminomatous GCTs (testicular and ovarian), additional therapy may not be necessary. However, close monitoring of patients is important.[7,8] The watch-and-wait approach requires scheduled serial physical examination, tumor marker determination, and primary tumor imaging to ensure that a recurrent tumor is detected without delay.

Sources: 7 · 8

Health professional · Treatment Option Overview for Childhood Extracranial GCTs

Chemotherapy

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

In the United States, the standard chemotherapy regimen for both adults and children with malignant nonseminomatous GCTs includes cisplatin, etoposide, and bleomycin. Adult patients receive weekly bleomycin throughout treatment (bleomycin, etoposide, and cisplatin [BEP]).[9-12] U.S. pediatric trials included patients aged 15 years and younger with testicular GCTs and patients aged 21 years and younger with ovarian and extragonadal GCTs. Patients received bleomycin only on day 1 of each cycle (cisplatin, etoposide, and bleomycin [PEb]).[3,13] The combination of carboplatin, etoposide, and bleomycin (JEb) underwent clinical investigation in the United Kingdom in children younger than 16 years. Treatment with this regimen produced event-free survival (EFS) rates by site and stage similar to those produced using treatment with PEb.[14,15]; [16][Level of evidence C1] For information about adult BEP and pediatric PEb and JEb chemotherapy dosing schedules, see Table 8.[3,9-11,13] In both adult and pediatric trials, the number of adolescent subjects was small. The optimal therapy for adolescents (aged ≥11 years) is not clear.[17]

Sources: 9 · 12 · 3 · 13 · 14 · 15 · 16 · Level of evidence C1 · Table 8 · 3 · 9 · 11 · 13 · 17

The use of JEb appears to be associated with fewer otologic toxic effects and renal toxic effects than does the use of PEb.[14] In a retrospective meta-analysis of data from the Children’s Oncology Group (COG) and the Children’s Cancer and Leukaemia Group germ cell studies conducted contemporaneously, the multivariate cure model showed no difference in 4-year EFS rates. The 4-year EFS rate was 86% (95% confidence interval [CI], 83%–89%) for patients who received the cisplatin regimen (n = 620) and 86% (95% CI, 79%–90%) for patients who received the carboplatin regimen (n = 163) (P = .87).[18][Level of evidence C1] However, PEb and JEb have not been compared in a randomized pediatric GCT trial.

Sources: 14 · 18 · Level of evidence C1

Table 8. Comparison of Adult BEP and Pediatric PEb and JEb Chemotherapy Dosing Schedules
RegimenBleomycinEtoposideCisplatinCarboplatin
BEP = bleomycin, etoposide, and cisplatin; GFR = glomerular filtration rate; JEb = carboplatin, etoposide, and bleomycin; PEb = cisplatin, etoposide, and bleomycin.
Adult BEP (every 21 days) [11,19]30 units/m2, days 1, 8, 15 (maximum 30 units)100 mg/m2, days 1–520 mg/m2, days 1–5
Pediatric PEb (every 21 days) [3,13]15 units/m2, day 1 (maximum 30 units)100 mg/m2, days 1–520 mg/m2, days 1–5
Pediatric JEb (every 21–28 days) [14]15 units/m2, day 3 (maximum 30 units)120 mg/m2, days 1–3600 mg/m2 or GFR-based dosing, day 2

Sources: 11 · 19 · 3 · 13 · 14

Several trials were conducted by the COG (previously the Children's Cancer Group and the Pediatric Oncology Group).[3,7,13] These trials explored the use of PEb for the treatment of localized gonadal GCT [3] and intensified regimens for patients with poor-risk features. The strategies included high-dose cisplatin (200 mg/m2) and cyclophosphamide or the protective agent amifostine.[13,20] None of these strategies had a significant effect on survival or decreased toxicity.

Sources: 3 · 7 · 13 · 3 · 13 · 20

The COG conducted a trial of compressed and reduced PEb chemotherapy (three cycles in 3 days) for patients with low-risk or intermediate-risk malignant GCTs. This study was designed as a noninferior trial with a P value of .1. The 4-year EFS rate of 89% was significantly lower than the rate for the historical control model (92%; P = .08).[21] However, the number of patients in each stratum was small, and further investigation in patients with lower-stage disease may be warranted.

Sources: 21

Health professional · Treatment Option Overview for Childhood Extracranial GCTs

Radiation Therapy

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Testicular and mediastinal seminomas in males and ovarian dysgerminomas in females are sensitive to radiation, but radiation therapy is rarely recommended because of the known late effects.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Transplant surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Health professional

Treatment of Mature and Immature Teratomas in Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Mature and immature teratomas arise primarily in the sacrococcygeal region of neonates and young children and in the ovaries of pubescent girls. Less commonly, these tumors are found in the testicular region of boys younger than 4 years, the mediastinum of adolescents, and other sites.[1-3] The primary treatment for teratomas is surgery with complete resection. Surgical options for sacrococcygeal teratomas are complex.

Sources: 1 · 3

Benign head and neck teratomas and immature teratomas can cause morbidity and mortality through obstruction. In preterm infants and neonates, head and neck teratomas and immature teratomas can cause significant airway compromise. In a single-institutional report, airway obstruction was overcome by using the ex utero intrapartum treatment (EXIT) procedure.[4] Complete resection of a teratoma can be achieved.

Sources: 4

Health professional · Treatment of Mature and Immature Teratomas in Children

Treatment of Mature Teratomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Health professional · Treatment of Mature and Immature Teratomas in Children / Treatment of Mature Teratomas

Standard treatment options for mature teratomas (sacrococcygeal sites)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The sacrococcygeal region is the primary tumor site for most benign and malignant germ cell tumors (GCTs) diagnosed in neonates, infants, and children younger than 4 years. These tumors occur more often in girls than in boys; ratios of 3:1 to 4:1 have been reported.[5]

Sources: 5

Sacrococcygeal tumors present in the following two clinical patterns related to the child’s age, tumor location, and likelihood of tumor malignancy:[1]

Sources: 1

Neonates: Neonatal tumors present at birth protruding from the sacral site. However, saccrococcygeal tumors may extend into the retroperitoneal space without outward protrusion. They are usually mature or immature teratomas.

Infants and young children: In infants and young children, tumors present as a palpable mass in the sacro-pelvic region, compressing the bladder or rectum. These pelvic tumors are more likely to be malignant. The older the child at presentation, the more likely a malignant component is present in addition to the teratoma. An early survey found that the rate of tumor malignancy was 48% for girls and 67% for boys older than 2 months at the time of sacrococcygeal tumor diagnosis, compared with a malignant tumor incidence of 7% for girls and 10% for boys younger than 2 months at the time of diagnosis.[6] The pelvic primary tumor site has been reported to be an adverse prognostic factor. This could be due to a delayed diagnosis because it was overlooked at birth or incomplete resection at the time of original surgery.[6-9]

Sources: 6 · 6 · 9

Standard treatment options for mature teratomas in a sacrococcygeal site include the following:

Surgery and observation.

Surgery is an essential component of treatment. Complete resection of the coccyx is vital to minimize the likelihood of tumor recurrence.[2]

Sources: 2

Health professional · Treatment of Mature and Immature Teratomas in Children / Treatment of Mature Teratomas

Standard treatment options for mature teratomas (nonsacrococcygeal sites)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Standard treatment options for mature teratomas in a nonsacrococcygeal site include the following:

Surgery and observation.

Children with mature teratomas, including mature teratomas of the mediastinum, can be treated with surgery and observation and have an excellent prognosis.[1,10]

Sources: 1 · 10

In a review of 153 children with nontesticular mature teratomas, the 6-year relapse-free survival rate was 96% for patients with completely resected disease and 55% for patients with incompletely resected disease.[2] Another series included 57 girls with mature teratomas of the ovary. Two patients experienced tumor recurrences (8 and 12 months after ovarian-sparing surgery), and seven patients developed metachronous tumors (as late as 79 months after initial diagnosis).[11][Level of evidence C1]

Sources: 2 · 11 · Level of evidence C1

A multidisciplinary team should treat and monitor neonates with head and neck GCTs. Although most head and neck GCTs are benign, they can be life-threatening and present significant challenges to surgeons, especially in newborns.[4] Some tumors develop malignant elements, which may change the treatment strategy.[12,13]

Sources: 4 · 12 · 13

Mature teratomas in the prepubertal testis are relatively common benign lesions and may be amenable to testis-sparing surgery.[14]

Sources: 14

Health professional · Treatment of Mature and Immature Teratomas in Children

Treatment of Immature Teratomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Health professional · Treatment of Mature and Immature Teratomas in Children / Treatment of Immature Teratomas

Treatment options for immature teratomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Treatment options for immature teratomas include the following:

Surgery and observation (stage I).

Sources: Surgery and observation (stage I)

Surgery and observation or chemotherapy (stages I–IV). The use of chemotherapy is controversial. For more information, see evidence on the role of chemotherapy for immature teratomas.

Sources: Surgery and observation or chemotherapy (stages I–IV) · evidence on the role of chemotherapy for immature teratomas

Health professional · Treatment of Mature and Immature Teratomas in Children / Treatment of Immature Teratomas / Treatment options for immature teratomas

Surgery and observation (stage I)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Immature teratomas in children are primarily managed with surgery and observation.

Evidence (surgery and observation for stage I disease):

A surgery-alone approach was investigated in a study by the Pediatric Oncology Group and Children's Cancer Group. Surgical resection followed by careful observation was used to treat patients with immature teratomas.[15]

Sources: 15

A surgery-alone approach was investigated in a study by the Pediatric Oncology Group and Children's Cancer Group. Surgical resection followed by careful observation was used to treat patients with immature teratomas.[15]

Surgery alone was curative for most children and adolescents with resected ovarian immature teratomas of any grade, even when elevated levels of serum alpha-fetoprotein (AFP) or microscopic foci of yolk sac tumor were present.

The 3-year event-free survival (EFS) rates were 97.8% for patients with ovarian tumors, 100% for patients with testicular tumors, and 80% for patients with extragonadal tumors.

Health professional · Treatment of Mature and Immature Teratomas in Children / Treatment of Immature Teratomas / Treatment options for immature teratomas

Surgery and observation or chemotherapy (stages I–IV)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The use of chemotherapy is controversial in the treatment of immature teratomas. There are no clinical trials supporting the use of chemotherapy in children. In adult women with ovarian tumors, surgery followed by chemotherapy has been the standard treatment approach since 1976.[16] As in children, there are no clinical trials supporting the use of chemotherapy in adults.

Sources: 16

Evidence (role of chemotherapy for immature teratomas):

A seminal article published in 1976 reported that most women with ovarian immature teratomas were treated with surgery and chemotherapy. This approach has remained standard practice in postpubertal females.[16]

Sources: 16

A report on pediatric patients aged 15 years and younger in the United Kingdom found that immature teratomas did not respond to chemotherapy.[17]

Sources: 17

A report from the Malignant Germ Cell Tumor International Collaborative (MaGIC) analyzed data from 98 pediatric patients and 81 adult patients with ovarian immature teratomas. Ninety pediatric patients underwent surgery alone. All 81 adult patients received adjuvant chemotherapy.[18][Level of evidence C1]

Sources: 18 · Level of evidence C1

A report from the Malignant Germ Cell Tumor International Collaborative (MaGIC) analyzed data from 98 pediatric patients and 81 adult patients with ovarian immature teratomas. Ninety pediatric patients underwent surgery alone. All 81 adult patients received adjuvant chemotherapy.[18][Level of evidence C1]

The 5-year EFS rate was 91% for pediatric patients and 98% for adult patients.

The overall survival (OS) rate was 83% for pediatric patients and 93% for adult patients.

There were no relapses in patients with grade I tumors. One adult patient with a grade II tumor relapsed after chemotherapy.

For pediatric patients with grade III, stage I/II tumors, the 5-year EFS rate was 92%. For patients with grade III, stage III tumors, the 5-year EFS rate was 52%.

For adult patients with grade III, stage I/II tumors, the 5-year EFS rate was 91%. For patients with grade III, stage III/IV tumors, the 5-year EFS rate was 65%.

Additional studies on the treatment of ovarian immature teratomas with chemotherapy are needed. For more information about the treatment of ovarian immature teratomas in postpubertal females, see Ovarian Germ Cell Tumors Treatment.

Sources: Ovarian Germ Cell Tumors Treatment

Health professional · Treatment of Mature and Immature Teratomas in Children / Treatment of Immature Teratomas / Treatment options for immature teratomas

Treatment options under clinical evaluation for immature teratomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AGCT1531 (NCT03067181) (Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with GCTs): Patients with ovarian pure-cell immature teratomas that are Children's Oncology Group stage I (International Federation of Gynecology and Obstetrics [FIGO] stage IA and IB), grade 2 or 3, and have an AFP level of less than 1,000 ng/mL are eligible for surgery and observation on this trial.

Sources: AGCT1531 (NCT03067181)

Health professional · Treatment of Mature and Immature Teratomas in Children

Follow-up After Treatment of Mature and Immature Teratomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

After successful resection, neonates diagnosed with benign mature and immature teratomas are closely observed with follow-up exams and serial serum AFP determinations. These tests are done for several years to ensure that AFP measurements normalize to expected physiological levels and to facilitate early detection of tumor relapse.[19,20] Several oncology groups have reported significant rates of recurrence among these benign tumors, ranging from 10% to 21%. Most relapses occur within 3 years of resection.[5,19,21,22]

Sources: 19 · 20 · 5 · 19 · 21 · 22

While there is no standard follow-up schedule, tumor markers are measured frequently for 3 years in all children. With early detection, recurrent malignant GCTs can be treated successfully with surgery and chemotherapy (OS rate, 92%).[23] Long-term survivors are monitored for complications of extensive surgery, which include constipation, fecal and urinary incontinence, and psychologically unacceptable cosmetic scars.[24]

Sources: 23 · 24

Health professional

Treatment of Malignant Gonadal GCTs in Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Health professional · Treatment of Malignant Gonadal GCTs in Children

Childhood Malignant Testicular GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Testicular GCTs

Malignant testicular GCTs in prepubertal males

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The role of surgery at diagnosis for germ cell tumors (GCTs) depends on patient age and tumor site, and treatment must be individualized. All malignant testicular GCTs should be resected. Resection may be followed by subsequent excision of residual masses after chemotherapy.

Testicular GCTs in children occur almost exclusively in boys younger than 5 years.[1,2] The initial surgical approach to evaluate a testicular mass in a young boy is important because a trans-scrotal biopsy can risk inguinal node metastasis.[3,4] Radical inguinal orchiectomy with initial high ligation of the spermatic cord is the procedure of choice.[5]

Sources: 1 · 2 · 3 · 4 · 5

Computed tomography or magnetic resonance imaging evaluation, with the additional information provided by elevated tumor markers, appears adequate for staging. Retroperitoneal dissection of lymph nodes is not beneficial in the staging of testicular GCTs in young boys.[3,4] Therefore, there may be no reason to risk the potential morbidity (e.g., impotence and retrograde ejaculation) associated with lymph node dissection.[6,7]

Sources: 3 · 4 · 6 · 7

A revised risk stratification was developed by the Malignant Germ Cell Tumor International Consortium (see Figure 4).[8]

Sources: Figure 4 · 8

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Testicular GCTs / Malignant testicular GCTs in prepubertal males

Standard treatment options for malignant GCTs in prepubertal males

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Standard treatment options for malignant GCTs in prepubertal males (aged <11 years) include the following:

Surgery and observation (stage I).

Sources: Surgery and observation (stage I)

Surgery and chemotherapy (stages II–IV).

Sources: Surgery and chemotherapy (stages II–IV)

The treatment options for malignant GCTs in prepubertal males differ by stage of disease.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Testicular GCTs / Malignant testicular GCTs in prepubertal males / Standard treatment options for malignant GCTs in prepubertal males

Surgery and observation (stage I)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Surgery and close follow-up observation are indicated to document that tumor marker levels normalize after resection.[3,9]

Sources: 3 · 9

Evidence (surgery and observation for stage I disease in prepubertal males):

A Children’s Cancer Group (CCG)/Pediatric Oncology Group (POG) clinical trial evaluated surgery followed by observation for boys aged 10 years or younger with stage I testicular tumors.[3,4]

Sources: 3 · 4

A Children’s Cancer Group (CCG)/Pediatric Oncology Group (POG) clinical trial evaluated surgery followed by observation for boys aged 10 years or younger with stage I testicular tumors.[3,4]

This treatment strategy resulted in a 6-year event-free survival (EFS) rate of 82%.

Boys who developed recurrent disease received salvage therapy with four cycles of standard-dose cisplatin, etoposide, and bleomycin (PEb), with a 6-year survival rate of 100%.

A subsequent Children’s Oncology Group (COG) study of 80 boys younger than 15 years with stage I disease included 15 boys aged 11 to 15 years who were treated with surgery and observation.[10][Level of evidence C1]

Sources: 10 · Level of evidence C1

A subsequent Children’s Oncology Group (COG) study of 80 boys younger than 15 years with stage I disease included 15 boys aged 11 to 15 years who were treated with surgery and observation.[10][Level of evidence C1]

The 4-year EFS rate was 80% for the 65 boys younger than 11 years at diagnosis and 48% for the 15 boys aged 11 years and older (P < .01). All patients' disease was eventually salvaged, with a 4-year overall survival (OS) rate of 100%.

Favorable prognostic factors were younger age, presence of pure yolk sac tumor, and lack of lymphovascular invasion by the primary tumor.

Adult testicular staging systems classify patients with lymphovascular invasion as stage IB. In the entire cohort, those with lymphovascular invasion had a lower 4-year EFS rate (62% vs. 84%).

A pooled analysis (from the studies above) provided more complete outcome data on patients with stage I disease who were treated with surgery and observation.[11][Level of evidence C2]

Sources: 11 · Level of evidence C2

A pooled analysis (from the studies above) provided more complete outcome data on patients with stage I disease who were treated with surgery and observation.[11][Level of evidence C2]

Most patients were prepubertal, but 13.2% of patients were adolescents (aged 13–15 years).

At a median follow-up of 56 months, all patients were alive.

There were 25 events.

On multivariate analysis, independent prognostic factors were age younger than 12 years (hazard ratio [HR], 8.87; P < .0001) and higher pT stage (pT2: HR, 7.31; P = .0017 and pT3: HR, 13.5; P = .0047).

A German study (MAHO 98) of 128 boys younger than 10 years with testicular GCTs, mostly stage I, also evaluated surgery followed by observation.[12][Level of evidence C1]

Sources: 12 · Level of evidence C1

A German study (MAHO 98) of 128 boys younger than 10 years with testicular GCTs, mostly stage I, also evaluated surgery followed by observation.[12][Level of evidence C1]

There were 49 patients with yolk sac tumors that were staged as IA after inguinal orchiectomy. Stage IA includes no evidence of lymphovascular invasion. The 5-year EFS rate was 95%, and the 5-year OS rate was 100% for this group. Two patients relapsed and then were cured after chemotherapy.

There were 12 patients who initially had trans-scrotal orchiectomy who were pathologically confirmed to have no lymphovascular invasion (would be considered stage IA, if not for surgery). Ten patients were observed who had no adverse events. Two patients relapsed (17%) and remained in continuous remission after chemotherapy. No patients had hemiscrotectomy. A long-standing question has been whether trans-scrotal orchiectomy necessitates chemotherapy or hemiscrotectomy.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Testicular GCTs / Malignant testicular GCTs in prepubertal males / Standard treatment options for malignant GCTs in prepubertal males

Surgery and chemotherapy (stages II–IV)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Surgery and chemotherapy with four cycles of standard PEb is a common treatment regimen for prepubertal males with stages II through IV disease. Patients treated with this regimen have OS rates exceeding 90%, suggesting that a reduction in therapy could be considered.[13,14]

Sources: 13 · 14

Surgery and treatment with four to six cycles of carboplatin, etoposide, and bleomycin (JEb) is an alternative treatment regimen.[9]

Sources: 9

Evidence (surgery and chemotherapy for stages II–IV disease in prepubertal males):

A CCG/POG clinical trial evaluated boys younger than 10 years with stage II tumors who were treated with four cycles of PEb after diagnosis.[13]

Sources: 13

A CCG/POG clinical trial evaluated boys younger than 10 years with stage II tumors who were treated with four cycles of PEb after diagnosis.[13]

The 6-year EFS and OS rates were 100%.

In the same CCG/POG clinical trial, boys and adolescents (aged 14 years and younger) with stage III and stage IV testicular tumors were treated with surgical resection followed by four cycles of standard-dose PEb or high-dose PEb (HD-PEb) therapy.[14]

Sources: 14

In the same CCG/POG clinical trial, boys and adolescents (aged 14 years and younger) with stage III and stage IV testicular tumors were treated with surgical resection followed by four cycles of standard-dose PEb or high-dose PEb (HD-PEb) therapy.[14]

The 6-year survival rate for males younger than 15 years with stage III and stage IV tumors was 100%.

The 6-year EFS rate for males younger than 15 years was 100% for stage III tumors and 94% for stage IV tumors.

The use of HD-PEb therapy did not improve the outcome for these boys but did cause increased incidence of otologic toxic effects.

European investigators have reported excellent outcomes for boys with testicular GCTs using surgery and observation for stage I tumors and JEb and other cisplatin-containing chemotherapy regimens for stage II, stage III, and stage IV tumors.[6,9]

Sources: 6 · 9

A phase III, single-arm COG trial (AGCT0132 [NCT00053352]) included 210 intermediate-risk patients (stages II–IV testicular, stages II–III ovarian, stages I–II extragonadal, or stage I gonadal tumors with subsequent recurrence). These patients received three, rather than four, cycles of PEb and the schedule was compressed from 5 days to 3 days per cycle. A parametric comparator model specified that the observed EFS rate would not be significantly less than 92%.[15][Level of evidence B4]

Sources: AGCT0132 · 15 · Level of evidence B4

A phase III, single-arm COG trial (AGCT0132 [NCT00053352]) included 210 intermediate-risk patients (stages II–IV testicular, stages II–III ovarian, stages I–II extragonadal, or stage I gonadal tumors with subsequent recurrence). These patients received three, rather than four, cycles of PEb and the schedule was compressed from 5 days to 3 days per cycle. A parametric comparator model specified that the observed EFS rate would not be significantly less than 92%.[15][Level of evidence B4]

The 4-year EFS rate was 89% (95% confidence interval, 83%–92%), which was significantly lower than the 92% threshold of the comparison model (P = .08).

In a post hoc analysis, the EFS rate was compared with similar patients treated with four cycles of PEb in two previous studies. Among 181 newly diagnosed patients, the 4-year EFS rate was 87%, compared with 92% for 92 comparable children in the historical cohort (P = .15).

The 4-year EFS rate was significantly associated with stage (stage I, 100%; stage II, 92%; stage III, 85%; and stage IV, 54%; P < .001).

These data do not support a reduction in the number of cycles of PEb from four to three.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Testicular GCTs

Malignant testicular GCTs in postpubertal males

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The treatment options described for prepubertal males may not be strictly applicable to postpubertal males. In particular, retroperitoneal lymph node dissection is a treatment option and may play a crucial role [16] in the initial treatment of patients or in subsequent treatment of patients with residual disease after chemotherapy for metastatic testicular GCT.[17,18] A meta-analysis showed that patients older than 11 years were at higher risk of recurrence.[8] The number of males aged 11 to 15 years with GCT is small; it is possible that these patients should be treated according to adult standards. For more information about the treatment of malignant testicular GCTs in postpubertal males, see Testicular Cancer Treatment.

Sources: 16 · 17 · 18 · 8 · Testicular Cancer Treatment

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Testicular GCTs / Malignant testicular GCTs in postpubertal males

Standard treatment options for malignant testicular GCTs in postpubertal males

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

For information about the treatment of malignant testicular GCTs in postpubertal males, see Testicular Cancer Treatment.

Sources: Testicular Cancer Treatment

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Testicular GCTs / Malignant testicular GCTs in postpubertal males

Treatment options under clinical evaluation for malignant testicular GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AGCT1531 (NCT03067181) (Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with GCTs): The aim of this trial is to reduce toxicity and maintain efficacy of treatment for patients with standard-risk GCTs. Patients with stage I malignant GCTs (low risk, age 0–50 years) will be treated with surgery and observation. Patients with intermediate-risk GCTs will be randomly assigned to receive cisplatin or carboplatin and bleomycin and etoposide. Children younger than 11 years will receive bleomycin with each cycle, and those aged 11 years and older will receive weekly bleomycin. Patients with pure seminoma or dysgerminoma are excluded from the trial.

Sources: AGCT1531 (NCT03067181)

Health professional · Treatment of Malignant Gonadal GCTs in Children

Childhood Malignant Ovarian GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Most ovarian neoplasms in children and adolescents are of germ cell origin.[19] Ovarian GCTs are very rare in young girls, but the incidence begins to increase in children aged approximately 8 or 9 years and continues to rise throughout adulthood.[1]

Sources: 19 · 1

Childhood malignant ovarian GCTs can be divided into germinomatous (dysgerminomas) and nongerminomatous malignant GCTs (i.e., yolk sac carcinomas, mixed GCTs, choriocarcinoma, and embryonal carcinomas).

For more information about childhood mature and immature teratomas arising in the ovary, see the Treatment of Mature Teratomas section. For more information about the treatment of ovarian GCT in postpubertal females, see Ovarian Germ Cell Tumors Treatment.

Sources: Treatment of Mature Teratomas · Ovarian Germ Cell Tumors Treatment

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs

Dysgerminomas of the ovary

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs / Dysgerminomas of the ovary

Standard treatment options for dysgerminomas of the ovary

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Standard treatment options for dysgerminomas of the ovary include the following:

Surgery and observation (stage I).

Sources: Surgery and observation (stage I)

Surgery and chemotherapy (stages II–IV).

Sources: Surgery and chemotherapy (stages II–IV)

The treatment options for dysgerminomas of the ovary differ by stage of disease.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs / Dysgerminomas of the ovary / Standard treatment options for dysgerminomas of the ovary

Surgery and observation (stage I)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

For stage I ovarian dysgerminomas, a cure can usually be achieved by unilateral salpingo-oophorectomy, conserving the uterus and opposite ovary, and close follow-up observation.[9,20-23]

Sources: 9 · 20 · 23

Evidence (surgery and observation for stage I dysgerminomas):

In three successive French Society of Pediatric Oncology studies (TGM-85, TGM-90, and TGM-95), the following was reported:[24][Level of evidence C1]

Sources: 24 · Level of evidence C1

In three successive French Society of Pediatric Oncology studies (TGM-85, TGM-90, and TGM-95), the following was reported:[24][Level of evidence C1]

Fifteen patients were identified as stage I, and all patients survived.

Before 1998, eight patients were treated with adjuvant radiation or chemotherapy. After a practice change in 1998, seven patients underwent surgery and observation.

One of the seven patients (14%) had a tumor event and responded to treatment with chemotherapy.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs / Dysgerminomas of the ovary / Standard treatment options for dysgerminomas of the ovary

Surgery and chemotherapy (stages II–IV)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

While advanced-stage ovarian dysgerminomas, like testicular seminomas, are highly curable with surgery and radiation therapy, the effects on growth, fertility, and risk of treatment-induced second malignancy in these young patients [25,26] make chemotherapy a more attractive adjunct to surgery.[27,28] Complete tumor resection is the goal for advanced dysgerminomas. Platinum-based chemotherapy can be given preoperatively to facilitate resection or postoperatively (after debulking surgery) to avoid mutilating surgical procedures.[23]

Sources: 25 · 26 · 27 · 28 · 23

Evidence (surgery and chemotherapy for stage II–IV dysgerminomas):

In a report from the French Society of Pediatric Oncology, 48 girls younger than 19 years (median age, 12.8 years) were registered; 20 patients had localized disease, 28 patients had locoregional disease, and no patients had metastases. Seven patients had positive para-aortic lymph nodes. Forty-seven patients underwent primary surgery. Before 1998, all patients with advanced disease received radiation therapy. After a practice change in 1998, patients were treated with platinum-based chemotherapy.[24][Level of evidence C1]

Sources: 24 · Level of evidence C1

In a report from the French Society of Pediatric Oncology, 48 girls younger than 19 years (median age, 12.8 years) were registered; 20 patients had localized disease, 28 patients had locoregional disease, and no patients had metastases. Seven patients had positive para-aortic lymph nodes. Forty-seven patients underwent primary surgery. Before 1998, all patients with advanced disease received radiation therapy. After a practice change in 1998, patients were treated with platinum-based chemotherapy.[24][Level of evidence C1]

The 5-year EFS rate was 91%, and the 5-year OS rate was 100%.

Side effects were not severe, and several patients became pregnant in later years.

A meta-analysis of patients with dysgerminoma by the Malignant Germ Cell Tumor International Consortium reported the following:[29]

Sources: 29

A meta-analysis of patients with dysgerminoma by the Malignant Germ Cell Tumor International Consortium reported the following:[29]

No difference was seen between patients who were treated with cisplatin (n = 70) (5-year EFS rate, 93%; OS rate, 96%) and patients who were treated with carboplatin (n = 56) (5-year EFS rate, 96%; OS rate, 96%).

This approach results in a high rate of cure and the preservation of menstrual function and fertility in most patients with dysgerminomas.[27,30]

Sources: 27 · 30

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs

Malignant nongerminomatous ovarian GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

A multidisciplinary approach is essential for treatment of ovarian GCTs. Various surgical subspecialists and the pediatric oncologist must be involved in clinical decisions. The surgical approach for pediatric ovarian GCTs is often guided by the expectation that reproductive function can be preserved.

The treatment of ovarian malignant GCTs that are not dysgerminomas or immature teratomas generally involves surgical resection and adjuvant chemotherapy.[31,32]

Sources: 31 · 32

The role for surgery at diagnosis depends on patient age and tumor site, and treatment must be individualized. The use of laparoscopy in children with ovarian GCTs has not been well studied.

The use of intraoperative frozen biopsy in pediatric and adolescent patients to determine the presence of malignancy to allow an ovarian-sparing procedure has been questioned. In a retrospective analysis from the COG AGCT0132 (NCT00053352) study, 60 of 131 eligible patients with ovarian tumors had both intraoperative frozen section and final paraffin section diagnoses available.[33] Intraoperative frozen section biopsy was incorrect 38% of the time (23 patients), and it confirmed the final diagnosis 76% of the time. In addition, central pathological review detected additional germ cell components in 23.7% of patients.

Sources: AGCT0132 (NCT00053352) · 33

Pediatric surgical guidelines to determine stage I disease have been published.[34] Adult surgical guidelines to determine stage are more extensive. For more information about staging of ovarian GCTs in postpubertal females, see the Stage Information for Ovarian Germ Cell Tumors section in Ovarian Germ Cell Tumors Treatment.

Sources: 34 · Stage Information for Ovarian Germ Cell Tumors

Strict surgical staging guidelines need to be followed to determine true stage I disease. Historically, in both pediatric and adult studies, comprehensive staging guidelines have not been followed. If strict surgical staging guidelines are not followed, surgery followed by chemotherapy, rather than surgery followed by observation, is the standard treatment.[9,13,35]

Sources: 9 · 13 · 35

A goal of surgical therapy for pediatric GCTs is to preserve reproductive function. If conservative surgery is the choice, a high rate of cure can be obtained with adjuvant chemotherapy, and adherence to strict surgical guidelines is not necessary.[36]

Sources: 36

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs / Malignant nongerminomatous ovarian GCTs

Standard treatment options for malignant nongerminomatous ovarian GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Standard treatment options for malignant nongerminomatous ovarian GCTs in prepubertal females include the following:

Surgery and observation (stage I following strict surgical staging guidelines).

Sources: Surgery and observation (stage I following strict surgical staging guidelines)

Surgery and chemotherapy (PEb) (purported stage I and stages II–IV).

Sources: Surgery and chemotherapy (PEb) (purported stage I and stages II–IV)

Standard treatment options for malignant nongerminomatous ovarian GCTs in postpubertal females include the following:

Surgery and chemotherapy (bleomycin, etoposide, and cisplatin [BEP]) (purported stage I and stages II–IV).

Sources: Surgery and chemotherapy (bleomycin, etoposide, and cisplatin [BEP]) (purported stage I and stages II–IV)

Standard treatment options for malignant nongerminomatous ovarian GCTs that cannot be resected initially include the following:

Biopsy followed by chemotherapy and surgery (initially unresectable tumor).

Sources: Biopsy followed by chemotherapy and surgery (initially unresectable tumor)

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs / Malignant nongerminomatous ovarian GCTs / Standard treatment options for malignant nongerminomatous ovarian GCTs

Surgery and observation for prepubertal females (stage I following strict surgical staging guidelines)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

When strict surgical staging guidelines are followed, surgery followed by observation may be an appropriate treatment choice for prepubertal females with stage I disease.

Evidence (surgery and observation for prepubertal females with stage I disease):

In a COG trial, 25 girls with stage I ovarian malignant GCTs were treated with surgery and observation.[34]

Sources: 34

In a COG trial, 25 girls with stage I ovarian malignant GCTs were treated with surgery and observation.[34]

The 4-year EFS rate was 52%.

Relapse was detected in 12 patients by tumor marker elevation (mean time, 2 months). All patients later received salvage therapy with three cycles of PEb. The 4-year OS rate was 96%; one patient's disease was not salvaged.

Similar results have been reported in other international pediatric trials, but the number of patients has been small.[9]

Sources: 9

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs / Malignant nongerminomatous ovarian GCTs / Standard treatment options for malignant nongerminomatous ovarian GCTs

Surgery and chemotherapy for prepubertal and postpubertal females (purported stage I and stages II–IV)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

A revised risk stratification was developed by the Malignant Germ Cell Tumor International Consortium (see Figure 4).[8]

Sources: Figure 4 · 8

Chemotherapy regimens with cisplatin (PEb) or carboplatin (JEb) have been used successfully in children.[9,13,14,20] BEP is a common regimen in young women with ovarian GCTs.[37,38] BEP differs from PEb with the addition of weekly bleomycin. This approach results in a high rate of cure and the preservation of menstrual function and fertility in most patients with nondysgerminomas.[32,35] For more information about the dosing schedules for BEP, PEb, and JEb, see Table 8.

Sources: 9 · 13 · 14 · 20 · 37 · 38 · 32 · 35 · Table 8

In prepubertal females with purported stage I ovarian tumors (when strict surgical staging guidelines are not followed) surgery followed by chemotherapy (four cycles of PEb) is an appropriate treatment choice and results in EFS and OS rates of 95%.[13,14]

Sources: 13 · 14

In postpubertal females with purported stage I ovarian tumors, chemotherapy after resection remains the standard treatment. In postpubertal females, the strategy of observation after surgery has not been established and is under investigation in the AGCT1531 (NCT03067181) trial.

Sources: AGCT1531 (NCT03067181)

In prepubertal and postpubertal females with stages II, III, or IV ovarian tumors, surgery and chemotherapy are considered standard treatments. Surgery and chemotherapy with four to six cycles of standard PEb is used to treat younger (prepubertal) girls,[13,14] and BEP is used to treat postpubertal girls.[37,38] Patients with normalization of tumor markers undergo imaging after four cycles of PEb, and any residual tumor is resected. Patients with residual viable tumor after surgery are considered refractory.

Sources: 13 · 14 · 37 · 38

Alternatively, surgery and chemotherapy with four to six cycles of JEb is a treatment option (as demonstrated in one study in which all patients were younger than 15 years).[9]

Sources: 9

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs / Malignant nongerminomatous ovarian GCTs / Standard treatment options for malignant nongerminomatous ovarian GCTs

Initially unresectable ovarian GCT

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Primary resection of ovarian GCT is usually attempted. However, in rare instances, primary resection of the ovary is not possible without undue risk of damage to adjacent structures. In these cases, an appropriate strategy is biopsy for diagnosis, followed by chemotherapy and then subsequent surgery for patients who have residual masses after undergoing chemotherapy.

Health professional · Treatment of Malignant Gonadal GCTs in Children / Childhood Malignant Ovarian GCTs

Treatment options under clinical evaluation for malignant ovarian GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AGCT1531 (NCT03067181) (Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with GCTs): The aim of this trial is to reduce toxicity and maintain efficacy of treatment for patients with standard-risk GCTs. Patients with stage I malignant GCTs (low risk, age 0–50 years) will be treated with surgery and observation. Patients with intermediate-risk GCTs will be randomly assigned to receive cisplatin or carboplatin and bleomycin and etoposide. Children younger than 11 years will receive bleomycin with each cycle, and those aged 11 years and older will receive weekly bleomycin. Patients with pure seminoma or dysgerminoma are excluded from the trial.

Sources: AGCT1531 (NCT03067181)

Health professional

Treatment of Malignant Extragonadal Extracranial GCTs in Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

In initial reports, children with extragonadal malignant germ cell tumors (GCTs), particularly those with advanced-stage (stage III or stage IV) disease, had the highest risk of treatment failure for any GCT presentation.[1,2] Subsequently, an analysis of data from 25 years of pediatric GCT studies in the United States and United Kingdom reported that children younger than 11 years with extragonadal stage III and stage IV GCTs had an event-free survival (EFS) rate of 85%, and adolescents with stage III and stage IV extragonadal disease had poorer outcomes (expected EFS rate, <70%).[3]

Sources: 1 · 2 · 3

The role of surgery at diagnosis for extragonadal tumors depends on patient age and tumor site, and treatment must be individualized. Depending on the clinical setting, the appropriate surgical approach may be primary resection, biopsy before chemotherapy, or no surgery (e.g., for a mediastinal primary tumor in a patient with a compromised airway and elevated tumor markers). An appropriate strategy may be biopsy at diagnosis followed by chemotherapy and subsequent surgery in selected patients who have residual masses after chemotherapy.

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children

Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Standard treatment options for malignant extragonadal extracranial GCTs in prepubertal children include the following:

Surgery and chemotherapy (stages I–IV).

Sources: Surgery and chemotherapy (stages I–IV)

Biopsy followed by chemotherapy with or without surgery (stages III and IV).

Sources: Biopsy followed by chemotherapy with or without surgery (stages III and IV)

The treatment of malignant extragonadal extracranial GCTs also depends on the site of disease. For more information, see the Site-specific considerations for malignant extragonadal extracranial GCTs section.

Sources: Site-specific considerations for malignant extragonadal extracranial GCTs

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children

Surgery and chemotherapy (stages I–IV)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Surgery and chemotherapy with four cycles of standard cisplatin, etoposide, and bleomycin (PEb) is one treatment option. Patients with stage I and stage II disease treated with this regimen had an overall survival (OS) rate of 90%, suggesting that a reduction in therapy may be considered.[1,4] Patients with stage III and stage IV disease had OS rates of higher than 80%.[1]

Sources: 1 · 4 · 1

An alternative treatment option is surgery and chemotherapy with carboplatin, etoposide, and bleomycin (JEb).[5] Stage III and stage IV patients treated with JEb had an OS rate similar to that with the PEb regimen.[5]

Sources: 5 · 5

Two pediatric intergroup trials for patients with high-risk disease investigated the use of high-dose cisplatin (200 mg/m2) in a randomized study and a subsequent study that added amifostine to high-dose cisplatin.[1] No benefit in OS was observed, and 75% of patients required hearing aids. A Children's Oncology Group (COG) trial of patients with high-risk disease investigated the addition of cyclophosphamide to standard-dose PEb. The addition of cyclophosphamide was feasible and well tolerated at all dose levels, but there was no evidence that adding cyclophosphamide improved efficacy.[6]

Sources: 1 · 6

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children

Biopsy followed by chemotherapy with or without surgery (stages III and IV)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

While outcomes have improved remarkably since the advent of platinum-based chemotherapy and the use of a multidisciplinary treatment approach, complete resection before chemotherapy may be possible in some patients without major morbidity.[1,5]

Sources: 1 · 5

However, for patients with locally advanced sacrococcygeal tumors, mediastinal tumors, or large pelvic tumors, tumor biopsy followed by preoperative chemotherapy may facilitate subsequent complete tumor resection and improve ultimate patient outcome. No decrease in OS has been noted for patients with malignant extragonadal GCTs who have had delayed resection after receiving chemotherapy.[5,7-9]

Sources: 5 · 7 · 9

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children

Site-specific considerations for malignant extragonadal extracranial GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The treatment of malignant extragonadal extracranial GCTs depends in part on the site of disease.

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children / Site-specific considerations for malignant extragonadal extracranial GCTs

Sacrococcygeal site

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Sacrococcygeal GCTs are common extragonadal tumors that occur in very young children, predominantly young females.[10] The tumors are usually diagnosed at birth, when large external lesions predominate (usually mature or immature teratomas), or later in the first years of life, when presacral lesions with higher malignancy rates predominate.[10]

Sources: 10 · 10

Malignant sacrococcygeal tumors are usually very advanced at diagnosis. Two-thirds of patients have locoregional disease, and metastases are present in 50% of patients.[8,11,12] Because of their advanced stage at presentation, the management of sacrococcygeal tumors requires a multimodal approach with platinum-based chemotherapy followed by delayed tumor resection.

Sources: 8 · 11 · 12

Platinum-based therapies, with either cisplatin or carboplatin, are the cornerstone of treatment. The PEb regimen or the JEb regimen produces EFS rates of 85%.[8,9] Surgery may be facilitated by preoperative chemotherapy. In any patient with a sacrococcygeal GCT, resection of the coccyx is mandatory.[8,9]

Sources: 8 · 9 · 8 · 9

Completeness of surgical resection is an important prognostic factor, as shown in the following circumstances:[8,9,13]

Sources: 8 · 9 · 13

Resected tumors with negative microscopic margins: EFS rates higher than 90%.

Resected tumors with microscopic margins: EFS rates of 75% to 85%.

Resected tumors with macroscopic residual disease: EFS rates lower than 40%.

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children / Site-specific considerations for malignant extragonadal extracranial GCTs

Mediastinal site

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Mediastinal GCTs account for 15% to 20% of malignant extragonadal extracranial GCTs in children.[5] The histology of mediastinal GCT is dependent on age, with teratomas predominating among infants and yolk sac tumors predominating among children aged 1 to 4 years.[7]

Sources: 5 · 7

Prepubertal children with mediastinal malignant teratomas are treated with tumor resection, which is curative in almost all patients.[7] Children with stage I to stage III nonmetastatic mediastinal GCTs who receive cisplatin-based chemotherapy have 5-year EFS and OS rates of 90%. However, patients with stage IV mediastinal tumors have EFS rates closer to 80%.[3,5,7]; [14][Level of evidence C1]

Sources: 7 · 3 · 5 · 7 · 14 · Level of evidence C1

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children / Site-specific considerations for malignant extragonadal extracranial GCTs

Retroperitoneal site

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Malignant GCTs located in the retroperitoneum or abdomen usually present in children younger than 5 years. Most of these tumors are advanced stage and locally unresectable at diagnosis.[15] A limited biopsy followed by platinum-based chemotherapy to shrink tumor bulk can lead to complete tumor resection in most patients. Despite the advanced-stage disease in most patients, the 6-year EFS rate using PEb was 83% in the Pediatric Oncology Group/Children's Cancer Group intergroup study.[15]

Sources: 15 · 15

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children / Site-specific considerations for malignant extragonadal extracranial GCTs

Head and neck site

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Although rare, benign and malignant GCTs can occur in the head and neck region, especially in infants. The airway is often threatened. Surgery for nonmalignant tumors and surgery plus chemotherapy for malignant tumors can be curative.[16][Level of evidence C2]

Sources: 16 · Level of evidence C2

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children

Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Postpubertal Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

In a study of prognostic factors in pediatric extragonadal malignant GCTs, age older than 12 years was the most important prognostic factor. In a multivariate analysis, children aged 12 years and older with thoracic tumors had six times the risk of death compared with children younger than 12 years with primary nonthoracic tumors.[17] In a subsequent meta-analysis, adolescents with stage III and stage IV extragonadal disease had poor outcomes (expected EFS rate, <70%).[3] Extragonadal disease of any stage is considered a poor risk factor in adolescents and young adults.[18]

Sources: 17 · 3 · 18

Standard treatment options for malignant extragonadal extracranial GCTs in postpubertal children include the following:

Surgery.

Chemotherapy (four cycles of bleomycin, etoposide, and cisplatin [BEP]).

Chemotherapy followed by surgery to remove residual tumor.

Enrollment in a clinical trial.

As with sacrococcygeal tumors, primary chemotherapy is usually necessary to facilitate surgical resection of mediastinal GCTs, and the completeness of resection is a very important prognostic indicator.[7,19] Survival rates for the older adolescent and young adult population with mediastinal tumors are generally lower than 60%.[3,17,20-22]; [23][Level of evidence C1]

Sources: 7 · 19 · 3 · 17 · 20 · 22 · 23 · Level of evidence C1

Patients with a malignant mediastinal primary tumor and extracranial metastases are at the highest risk of developing brain metastases and are monitored closely for signs and symptoms of central nervous system involvement.[24][Level of evidence C1] For more information about the treatment of adult patients, see Extragonadal Germ Cell Tumors Treatment.

Sources: 24 · Level of evidence C1 · Extragonadal Germ Cell Tumors Treatment

Health professional · Treatment of Malignant Extragonadal Extracranial GCTs in Children

Treatment Options Under Clinical Evaluation for Malignant Extragonadal Extracranial GCTs

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

AGCT1531 (NCT03067181) (Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with GCTs): The aim of this trial is to reduce toxicity and maintain efficacy of treatment for patients with standard-risk GCTs. Patients with stage I malignant GCTs (low risk, age 0–50 years) will be treated with surgery and observation. Patients with intermediate-risk GCTs will be randomly assigned to receive cisplatin or carboplatin and bleomycin and etoposide. Children younger than 11 years will receive bleomycin with each cycle, and those aged 11 years and older will receive weekly bleomycin. Patients with pure seminoma or dysgerminoma are excluded from the trial.

Sources: AGCT1531 (NCT03067181)

Health professional

Treatment of Recurrent Malignant GCTs in Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Only a small number of children and adolescents with extracranial germ cell tumors (GCTs) have a recurrence.[1,2] Reports regarding the treatment and outcome of these children are based on small studies.[3]

Sources: 1 · 2 · 3

Treatment options for recurrent pediatric GCTs are modeled after treatment options in adult clinical trials. Information about ongoing National Cancer Institute (NCI)–supported clinical trials is available from the NCI website.

Sources: NCI website

Health professional · Treatment of Recurrent Malignant GCTs in Children

Standard Treatment Options for Recurrent Malignant GCTs in Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Standard treatment options for recurrent childhood malignant GCTs include the following:

Surgery alone.

Surgery with neoadjuvant or adjuvant chemotherapy.

Sources: Surgery with neoadjuvant or adjuvant chemotherapy

For information about salvage therapy after observation for patients with stage I disease, see the following sections:

Surgery and Observation section of the Treatment Option Overview for Childhood Extracranial GCTs section.

Sources: Surgery and Observation · Treatment Option Overview for Childhood Extracranial GCTs

Surgery and observation (stage I) section of the Malignant testicular GCTs in prepubertal males section.

Sources: Surgery and observation (stage I) · Malignant testicular GCTs in prepubertal males

Surgery and observation for prepubertal females (stage I following strict surgical staging guidelines) section of the Malignant nongerminomatous ovarian GCTs section.

Sources: Surgery and observation for prepubertal females (stage I following strict surgical staging guidelines) · Malignant nongerminomatous ovarian GCTs

Health professional · Treatment of Recurrent Malignant GCTs in Children / Standard Treatment Options for Recurrent Malignant GCTs in Children

Surgery with neoadjuvant or adjuvant chemotherapy

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Reports of salvage treatment strategies used in adult recurrent GCTs include larger numbers of patients, but the differences between children and adults regarding the location of the primary GCT site, pattern of relapse, and the biology of childhood GCTs may limit the applicability of adult salvage approaches to children. In adults with recurrent GCTs, several chemotherapy combinations (most include the addition of paclitaxel and ifosfamide to a platinum compound) have achieved relatively good disease-free status.[4-9] A combination of paclitaxel and gemcitabine has demonstrated activity in adults with testicular GCTs who relapsed after high-dose chemotherapy and hematopoietic stem cell transplant (HSCT).[10]

Sources: 4 · 9 · 10

Among children with benign sacrococcygeal tumors who recur, a malignant component may be present at the primary tumor site. For these children, complete surgical resection of the recurrent tumor and coccyx (if not done originally) is the basis of salvage treatment. Preoperative chemotherapy with cisplatin, etoposide, and bleomycin (PEb) may assist the surgical resection. In patients who had a malignant sacrococcygeal tumor that recurred after PEb treatment, surgery and additional chemotherapy may be warranted.[3]

Sources: 3

In a phase II Children’s Oncology Group (COG) trial (AGCT0521 [NCT00467051]), 20 patients younger than 21 years who relapsed after PEb therapy received two cycles of paclitaxel, ifosfamide, and carboplatin (TIC). Responses were then assessed by a combination of Response Evaluation Criteria In Solid Tumors (RECIST) criteria and marker decline. Eight patients had partial responses, ten patients had stable disease, and two patients had progressive disease. This chemotherapy regimen produced a combined response rate of 44%.[11]

Sources: AGCT0521 [NCT00467051] · 11

Health professional · Treatment of Recurrent Malignant GCTs in Children

Nonstandard Treatment Options for Recurrent Malignant GCTs in Children

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Health professional · Treatment of Recurrent Malignant GCTs in Children / Nonstandard Treatment Options for Recurrent Malignant GCTs in Children

High-dose (HD) chemotherapy and hematopoietic stem cell rescue

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

The role of HD chemotherapy and hematopoietic stem cell rescue for recurrent pediatric GCTs is not established, despite anecdotal reports. In one European series, 10 of 23 children with relapsed extragonadal GCTs achieved long-term disease-free survival (median follow-up, 66 months) after receiving HD chemotherapy with stem cell support.[12] Additional study in children and adolescents is needed. For more information about transplant, see Pediatric Autologous Hematopoietic Stem Cell Transplant and Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer.

Sources: 12 · Pediatric Autologous Hematopoietic Stem Cell Transplant · Pediatric Hematopoietic Stem Cell Transplant and Cellular Therapy for Cancer

HD chemotherapy with autologous stem cell rescue has been explored as a treatment for adults with recurrent testicular GCTs. HD chemotherapy plus hematopoietic stem cell rescue has been reported to cure adult patients with relapsed testicular GCTs, even as third-line therapy and in cisplatin-refractory patients.[10,13-15] A small study also demonstrated efficacy in adolescents and women with ovarian GCTs.[16][Level of evidence C1] While some studies support this approach,[10,14,15,17,18] others do not.[19,20] Salvage attempts using HD chemotherapy regimens may be of little benefit if the patient is not clinically disease free at the time of HSCT.[13,21]

Sources: 10 · 13 · 15 · 16 · Level of evidence C1 · 10 · 14 · 15 · 17 · 18 · 19 · 20 · 13 · 21

Health professional · Treatment of Recurrent Malignant GCTs in Children / Nonstandard Treatment Options for Recurrent Malignant GCTs in Children

Radiation therapy followed by surgery (for brain metastases)

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

In a very small pediatric study, patients with nongerminomatous brain metastases responded to radiation therapy. In the German Maligne Keimzelltümoren (MAKEI) studies, radiation therapy and surgery for patients with brain metastases provided palliation and occasional long-term survival.[22,23][Level of evidence C1] A meta-analysis showed that radiation therapy did not improve outcome compared with surgery and radiation. However, the number of patients treated with radiation therapy was too small to accurately assess outcome.[24]

Sources: 22 · 23 · Level of evidence C1 · 24

Health professional · Treatment of Recurrent Malignant GCTs in Children

Treatment Options Under Clinical Evaluation for Recurrent Malignant GCTs in Children and Adolescents

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024. Captured 2026-09-09.

Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

For patients · General Information About Childhood Extracranial Germ Cell Tumors

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

The prognosis and treatment options depend on the following:

Sources: prognosis

The child's age and general health.

The stage of the cancer (whether it has spread to nearby areas, lymph nodes, or to other places in the body).

Sources: stage

Where the tumor first began to grow.

The type of germ cell tumor.

How well the tumor responds to treatment.

Sources: responds

Whether the child has gonadal dysgenesis.

Whether the tumor can be completely removed by surgery.

Whether the cancer has just been diagnosed or has recurred (come back).

Sources: recurred

The prognosis for childhood extracranial germ cell tumors, especially ovarian germ cell tumors, is good.

For patients · Stages of Childhood Extracranial Germ Cell Tumors / Stages are used to describe the different types of extracranial germ cell tumors.

Childhood extracranial germ cell tumors usually do not come back after treatment.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Recurrent childhood extracranial germ cell tumor is cancer that has come back after it has been treated. The cancer may come back in the same place or in other parts of the body.

Sources: Recurrent

Most germ cell tumors do not recur (come back) after treatment. If they do recur, they usually come back within 3 years of surgery. About half of the teratomas that recur in the sacrum or coccyx are cancer, so follow-up is important.

Sources: germ cell tumors · recur · teratomas · sacrum · coccyx · follow-up

For patients

Treatment Option Overview

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

There are different types of treatment for children with extracranial germ cell tumors.

Children with extracranial germ cell tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Observation

Chemotherapy

New types of treatment are being tested in clinical trials.

New types of treatment are being tested in clinical trials.

High-dose chemotherapy with stem cell transplant

Radiation therapy

Treatment for childhood extracranial germ cell tumors may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for children with extracranial germ cell tumors.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Different types of treatments are available for children with extracranial germ cell tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.

Sources: extracranial germ cell tumors · standard · clinical trials · research study · cancer

Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.

For patients · Treatment Option Overview

Children with extracranial germ cell tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other health care providers who are experts in treating children with extracranial germ cell tumors and who specialize in certain areas of medicine. These may include the following specialists:

Sources: pediatric oncologist · health care providers · medicine · specialists

Pediatrician.

Sources: Pediatrician

Pediatric surgeon.

Sources: Pediatric surgeon

Pediatric hematologist.

Sources: Pediatric hematologist

Radiation oncologist.

Sources: Radiation oncologist

Endocrinologist.

Sources: Endocrinologist

Pediatric nurse specialist.

Sources: Pediatric nurse specialist

Rehabilitation specialist.

Sources: Rehabilitation specialist

Child life professional.

Sources: Child life professional

Psychologist.

Sources: Psychologist

Social worker.

Sources: Social worker

Geneticist.

Sources: Geneticist

Fertility specialist.

Sources: Fertility specialist

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Surgery to completely remove the tumor is done whenever possible. If the tumor is very large, chemotherapy may be given first, to make the tumor smaller and decrease the amount of tissue that needs to be removed during surgery. A goal of surgery is to keep reproductive function. The following types of surgery may be used:

Sources: Surgery · tumor · chemotherapy · tissue · reproductive

Resection: Surgery to remove tissue or part or all of an organ.

Sources: Resection · organ

Radical inguinal orchiectomy: Surgery to remove one or both testicles through an incision (cut) in the groin.

Sources: inguinal orchiectomy · testicles · incision · groin

Unilateral salpingo-oophorectomy: Surgery to remove one ovary and one fallopian tube on the same side.

Sources: Unilateral salpingo-oophorectomy · ovary · fallopian tube

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy after surgery to kill any cancer cells that are left. Treatment given after surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: cells · adjuvant therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Observation

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Observation is closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change. For children with extracranial germ cell tumors, this includes physical exams, imaging tests, and tumor marker tests.

Sources: monitoring · condition · signs · symptoms · physical exams · imaging tests · tumor marker tests

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Systemic chemotherapy is used to treat extracranial germ cell tumors.

Sources: drugs · cells · injected · vein · systemic chemotherapy

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Learn more at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

High-dose chemotherapy with stem cell transplant

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: blood · Stem cell transplant · Stem cells · bone marrow · donor · infusion

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Radiation therapy

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. External radiation therapy is being studied for the treatment of childhood extracranial germ cell tumors that have come back.

Sources: Radiation therapy · x-rays · radiation · External radiation therapy

For patients · Treatment Option Overview

Treatment for childhood extracranial germ cell tumors may cause side effects.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following:

Sources: late effects

Physical problems, such as infertility, trouble hearing and kidney problems.

Sources: infertility · kidney

Changes in mood, feelings, thinking, learning, or memory.

Second cancers (new types of cancer), such as leukemia or malignant melanoma.

Sources: Second cancers · leukemia

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. For more information, see Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).

For childhood extracranial germ cell tumors, follow-up may include regular physical exams, tumor marker tests, and imaging tests such as CT scan, MRI or chest x-ray.

Sources: CT scan · MRI · chest x-ray

For patients

Treatment of Childhood Mature and Immature Teratomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed mature teratomas includes the following:

Sources: diagnosed · mature teratomas

Surgery to remove the tumor followed by observation.

Sources: Surgery · tumor · observation

Treatment of newly diagnosed immature teratomas includes the following:

Sources: immature teratomas

Surgery to remove the tumor followed by observation for stage I tumors.

Surgery to remove the tumor for stage I–IV tumors. In young children, surgery is followed by observation; the use of chemotherapy after surgery is controversial. In adolescents and young adults, chemotherapy is given after surgery.

Sources: chemotherapy · adolescents

Sometimes a mature or immature teratoma also has malignant cells. A teratoma with malignant cells may need to be treated differently.

Sources: malignant · cells · teratoma

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Malignant Testicular Germ Cell Tumors

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed malignant testicular germ cell tumors may include the following:

Sources: diagnosed · malignant · testicular germ cell tumors

For boys younger than 11 years:

Surgery (radical inguinal orchiectomy) followed by observation for stage I tumors.

Sources: Surgery · inguinal orchiectomy · observation · tumors

Surgery (radical inguinal orchiectomy) followed by chemotherapy for stage II–IV tumors and repeat surgery to remove any remaining tumor.

Sources: chemotherapy

A clinical trial of a new regimen of surgery followed by observation for stage I tumors or chemotherapy for stage II–IV tumors.

Sources: clinical trial · regimen

For boys 11 years and older:

Malignant testicular germ cell tumors in boys 11 years and older are treated differently than they are in young boys. For more information, see Testicular Cancer Treatment.

Sources: Testicular Cancer Treatment

Surgery to remove the tumor. Sometimes lymph nodes in the abdomen are also removed.

Sources: lymph nodes · abdomen

A clinical trial of a new regimen of surgery followed by observation for stage I tumors or chemotherapy for stage II–IV tumors.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Malignant Ovarian Germ Cell Tumors

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For patients · Treatment of Malignant Ovarian Germ Cell Tumors

Dysgerminomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed stage I dysgerminomas of the ovary may include the following:

Sources: diagnosed · dysgerminomas · ovary

Surgery (unilateral salpingo-oophorectomy) followed by observation. Chemotherapy may be given if tumor marker levels do not decrease after surgery or the tumor comes back.

Sources: Surgery · unilateral salpingo-oophorectomy · observation · Chemotherapy · tumor marker · tumor

A clinical trial of a new regimen of surgery followed by observation.

Sources: clinical trial · regimen

Treatment of newly diagnosed stages II–IV dysgerminomas of the ovary may include the following:

Surgery (unilateral salpingo-oophorectomy) followed by chemotherapy.

Chemotherapy to shrink the tumor, followed by surgery (unilateral salpingo-oophorectomy).

For patients · Treatment of Malignant Ovarian Germ Cell Tumors

Nongerminomas

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed nongerminomas of the ovary, such as yolk sac tumors, mixed germ cell tumors, choriocarcinoma, and embryonal carcinomas, in young girls may include the following:

Sources: diagnosed · nongerminomas · ovary · yolk sac tumors · mixed germ cell tumors · choriocarcinoma · embryonal · carcinomas

Surgery followed by observation for stage I tumors.

Sources: Surgery · observation · tumors

Surgery followed by chemotherapy for stage I–IV tumors.

Sources: chemotherapy

A clinical trial of a new regimen of surgery followed by observation for stage I tumors or chemotherapy for stage II–IV.

Sources: clinical trial · regimen

Treatment of newly diagnosed nongerminomas of the ovary in adolescents and young women may include the following:

Sources: adolescents

Surgery and chemotherapy for stage I–IV tumors.

A clinical trial of a new regimen of surgery followed by observation for stage I or chemotherapy for stage II–IV.

Treatment of newly diagnosed nongerminomas of the ovary that cannot be removed by primary surgery without risk to nearby tissue may include the following:

Sources: primary · tissue

Biopsy followed by chemotherapy and surgery.

Sources: Biopsy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Malignant Extragonadal Extracranial Germ Cell Tumors

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed childhood malignant extragonadal extracranial germ cell tumors in young children may include the following:

Sources: diagnosed · malignant · extragonadal extracranial germ cell tumors

Surgery and chemotherapy for stage I–IV tumors.

Sources: Surgery · chemotherapy · tumors

Biopsy followed by chemotherapy with or without surgery for stage III and IV tumors.

Sources: Biopsy

In addition to stage of the disease, treatment of malignant extragonadal extracranial germ cell tumors also depends on where the tumor formed in the body:

Sources: stage

For tumors in the sacrum or coccyx, chemotherapy to shrink the tumor followed by surgery to remove the tumor and coccyx.

Sources: sacrum · coccyx

For tumors in the mediastinum, chemotherapy before or after surgery to remove the tumor in the mediastinum.

Sources: mediastinum

For tumors in the abdomen, biopsy followed by chemotherapy to shrink the tumor and surgery to remove the tumor in the abdomen.

Sources: abdomen · biopsy

For tumors in the head and neck, surgery to remove the tumor in the head or neck, which may be followed by chemotherapy if the tumor is cancer.

Treatment of newly diagnosed childhood malignant extragonadal extracranial germ cell tumors in adolescents and young adults may include the following:

Sources: adolescents

Surgery.

Chemotherapy.

Chemotherapy followed by surgery to remove the tumor.

A clinical trial of a new regimen of surgery followed by observation for stage I tumors or chemotherapy for stage II–IV tumors.

Sources: clinical trial · regimen · observation

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Childhood Malignant Extracranial Germ Cell Tumors

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: July 19, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of recurrent childhood extracranial germ cell tumors may include the following:

Sources: extracranial germ cell tumors

Surgery.

Sources: Surgery

Chemotherapy given before or after surgery, for most malignant extracranial germ cell tumors including immature teratomas, malignant testicular germ cell tumors, and malignant ovarian germ cell tumors.

Sources: Chemotherapy · malignant · immature teratomas · testicular germ cell tumors · ovarian germ cell tumors

Chemotherapy for recurrent malignant testicular germ cell tumors and recurrent nongerminomas of the ovary that were stage I at diagnosis.

Sources: recurrent · nongerminomas · ovary

High-dose chemotherapy and stem cell transplant.

Sources: High-dose chemotherapy · stem cell transplant

Radiation therapy followed by surgery to remove cancer that has spread to the brain.

Sources: Radiation therapy · cancer

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

NCT00053352 · COMPLETED · phase3

Childhood Embryonal Tumor, Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant...

ClinicalTrials.gov record

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

NCT00467051 · COMPLETED · phase2

Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell...

ClinicalTrials.gov record

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

NCT03067181 · RECRUITING · phase3

Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian...

ClinicalTrials.gov record

Disease and treatment settings

Childhood Extracranial Germ Cell Tumors

Disease and treatment setting

Extracranial Germ Cell Tumors in children and adolescents

Childhood Extracranial Germ Cell Tumors

Disease and treatment setting

Initially unresectable ovarian GCT

recurrent Childhood Extracranial Germ Cell Tumors

Disease and treatment setting

Treatment of Recurrent Malignant GCTs in Children

Stage I Childhood Extracranial Germ Cell Tumors

Disease and treatment setting

Surgery and observation (stage I)